<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230316057738N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-19</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of tranexamic acid drug on bleeding and surgical outcomes of myoma removal through hysteroscope</public_title>
      <acronym>Tranexamic acid (TXA) - Normal salin (N.S)</acronym>
      <scientific_title>Investigating the effect of intrauterine tranexamic acid on bleeding  and the outcome of it in hysteroscopic myomectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69579</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use the Restricted randomization method of block block randomization 1:1, and the patients will be divided into two groups: placebo (30 people) or intervention (30 people) and the drug intervention group (tranexamic acid) 10 mg/kg) and placebo (normal saline) will be given to the other group. (Blocking is usually used in order to balance the number of samples allocated to each of the studied groups. This feature helps researchers to increase the number of samples in cases where intermediate analyzes are needed during the sampling process. allocated to each of the studied groups is the same) the size of all the blocks is equal and in this experiment we will have two groups of 6 blocks (including 3 participants in the intervention group and 3 participants in the control group) had The randomization tool is also used from software allocation random sequence generation software, which in addition to simple randomization, these random sequence generation software are capable of generating random sequence by block method, Blinding description: An independent person (statistician) who is involved in the treatment or collection of data will be sealed with consecutive numbers. The principal investigator, the patients, and the surgeon performing the surgery will all be blinded to the trial.
All participants will undergo a thorough clinical evaluation including: detailed history, general and pelvic examination, transvaginal ultrasound to determine the number, size and location of myomas. After preparing the history and clinical examinations, blood samples of the patients will be prepared and the necessary tests (CBC), PT, PTT and INR will be done for them before the surgery. Also, drug or placebo is prescribed using a specific coding system, and the surgical team and the patient themselves do not know the type of drug used.</study_design>
      <phase>3</phase>
      <hc_freetext>Uterus myoma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: as soon as the hysteroscope enters the uterus, an ampoule of tranexamic acid from Iran Daru 10 mg/kg will be injected into the uterus.p:. Intervention 2: Control group: As soon as the hysteroscope enters the uterus, 5 cc of normal saline will be injected into the uterus.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All of datas

When:
Starting from six months after the publication of the article

To whom:
Researchers, students and doctors

Conditions:
To conduct a clinical trial

Where to obtain:
Public or scientific responsible person

How to obtain:
Send the proposal to the responsible person's email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nadia Arabpour amroudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vasal Alley 1 , Vasal St.</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7617945661</zip>
        <telephone>+98 34 3216 8180</telephone>
        <email>arabpour.nadia@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nadia Arabpour Amroudi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vasal Alley 1, Vasal St.,</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7617945661</zip>
        <telephone>+98 34 3216 8180</telephone>
        <email>arabpour.nadia@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Have a single myoma
Grade 0, 1, and 2 myomas
Myomas smaller than 4 cm</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Have intracranial bleeding
Have any sensitivity to the drug tranexamic acid
Have thromboembolic and ischemic heart diseases
There are uterine abnormalities
Have an active pelvic infection
Have a history of hemorrhagic disease
Pregnancy
Previous hystreroscopy surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>D25.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Leiomyoma of uterus, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: as soon as the hysteroscope enters the uterus, an ampoule of tranexamic acid from Iran Daru 10 mg/kg will be injected into the uterus.p:</i_keyword>
      <i_keyword>Control group: As soon as the hysteroscope enters the uterus, 5 cc of normal saline will be injected into the uterus</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Better vision during surgery. Timepoint: During surgery. Method of measurement: Surgeon rating.</prim_outcome>
      <prim_outcome>Bleeding during surgery. Timepoint: During surgery. Method of measurement: Surgeon rating.</prim_outcome>
      <prim_outcome>Duration of operation. Timepoint: From the beginning of surgery to the end of surgery. Method of measurement: Minutes.</prim_outcome>
      <prim_outcome>Hemoglobin reduction rate. Timepoint: Before the operation and 24 hours after the operation. Method of measurement: Milligram on deciliter.</prim_outcome>
      <prim_outcome>Complications of the operation. Timepoint: During or after surgery. Method of measurement: Patient symptoms.</prim_outcome>
      <prim_outcome>The completeness of the operation in one step. Timepoint: One month after surgery. Method of measurement: Sonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-01</approval_date>
        <contact_name>Ethics Committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>University of Medical Sciences Campus,The beginning of Haft Bagh Alavi Boulevard, Kerman, Iran Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
